SCHEMBL633692

SCHEMBL633692

Cc1cc(NC(=O)c2sccc2NCc2c[nH]c3ncccc23)ccc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.45
KIT P10721 2/20 0.45
CYP3A4 P08684 2/20 0.45
RAF1 P04049 1/20 0.45
LCK P06239 1/20 0.45
RET P07949 1/20 0.45
MAP3K20 Q9NYL2 1/20 0.45
RIPK3 Q9Y572 1/20 0.45
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
BRAF P15056 1/20 0.40
MAPT P10636 5/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NAMPT P43490 1/20 0.39
MTNR1A P48039 1/20 0.38
ITGB2 P05107 1/20 0.38
ICAM1 P05362 1/20 0.38
ITGAL P20701 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27615043 0.89 KDR (0.44) KDRKITCYP3A4RAF1LCK
SCHEMBL633872 0.84 KDR (0.59) KDRKITCYP3A4RAF1LCK
SCHEMBL633921 0.83 KDR (0.64) KDRKITCYP3A4RAF1LCK
SCHEMBL635166 0.81 KIT (0.55) KDRKITCYP3A4RAF1LCK
SCHEMBL3395765 0.79 KDR (0.71) KDRKITCYP3A4RAF1LCK
SCHEMBL13409673 0.78 CYP3A4 (0.49) KDRKITCYP3A4RAF1LCK
SCHEMBL633659 0.74 KIT (0.69) KDRKITCYP3A4RAF1LCK
SCHEMBL27615059 0.72 KDR (0.63) KDRKITCYP3A4RAF1LCK
SCHEMBL633871 0.72 KIT (0.54) KDRKITCYP3A4RAF1LCK
SCHEMBL5790468 0.70 KDR (0.63) KDRKITCYP3A4RAF1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590328-B1 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2012-02-22 EP claimed
WO-2010088000-A2 ANTIFIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2010-08-05 WO claimed
US-6949563-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2005-09-27 US claimed
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2004-09-23 US claimed
EP-1590328-B1 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2012-02-22 EP disclosed
WO-2010088000-A2 ANTIFIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2010-08-05 WO disclosed
US-7696225-B2 (2-carboxamido)(3-Amino) thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
US-7524859-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2009-04-28 US disclosed
EP-1590328-A4 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2007-09-19 EP disclosed
EP-1807419-A1 (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS OSI Pharmaceuticals, Inc. (US) 2007-07-18 EP disclosed
US-20060247275-A1 (2-carboxamido)(3-amino)thiophene compounds CREW ANDREW P 2006-11-02 US disclosed
US-7101893-B2 (2-Carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2006-09-05 US disclosed
WO-2006047574-A1 (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2006-05-04 WO disclosed
EP-1590328-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI Pharmaceuticals, Inc. (US) 2005-11-02 EP disclosed
US-6949563-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2005-09-27 US disclosed
US-20050192320-A1 (2-Carboxamido)(3-amino)thiophene compounds CREW ANDREW P (US) 2005-09-01 US disclosed
US-20050154014-A1 (2-carboxamido)(3-amino) thiophene compounds OSI PHARMACEUTICALS, INC. 2005-07-14 US disclosed
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2004-09-23 US disclosed
WO-2004063330-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds ABL1, NAT1, KRAS KDR 869/4885KIT 1833/4885CYP3A4 150/4885
US-20050154014-A1 (2-carboxamido)(3-amino) thiophene compounds AADAC, PAM, TPMT KDR 2418/4885KIT 4457/4885CYP3A4 870/4885
US-20060247275-A1 (2-carboxamido)(3-amino)thiophene compounds PCNA, MKI67, MYC KDR 1639/4885KIT 325/4885CYP3A4 3686/4885
US-20050192320-A1 (2-Carboxamido)(3-amino)thiophene compounds PCNA, MKI67, TPMT KDR 1769/4885KIT 289/4885CYP3A4 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.